Triopsy

Triopsy is a private, early-stage medical device and digital health company focused on transforming the prostate biopsy procedure. Its core innovation is a fully integrated system comprising a specialized needle, an actuator for controlled sampling, a specimen transport container, and cloud-based laboratory software, all working together to standardize the biopsy workflow from procedure to pathology. The company targets the significant clinical problem of biopsy sampling error and tissue fragmentation, which can lead to misdiagnosis and delayed treatment in prostate cancer. By improving tissue yield and integrity, Triopsy seeks to enhance diagnostic accuracy, streamline clinician collaboration, and ultimately improve patient care.

An integrated biopsy system comprising a high-yield needle, controlled-depth actuator, specimen transport for orientation integrity, and cloud-based lab software to standardize and connect the biopsy workflow from procedure to pathology.

Triopsy competes against large, established medical device companies (e.g., BD, Boston Scientific) that supply standard core biopsy needles and systems. Its differentiation lies in its fully integrated platform designed specifically to solve tissue fragmentation and orientation loss. It may also face competition from other startups focused on biopsy precision or digital pathology, but its combination of hardware and software for the entire workflow appears unique.